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Stress responses from the
endoplasmic reticulum in cancer
Hironori Kato and Hideki Nishitoh*
Laboratory of Biochemistry and Molecular Biology, Department of Medical Sciences, University of Miyazaki, Miyazaki, Japan
The endoplasmic reticulum (ER) is a dynamic organelle that is essential for multiple
cellular functions. During cellular stress conditions, including nutrient deprivation and
dysregulation of protein synthesis, unfolded/misfolded proteins accumulate in the ER
lumen, resulting in activation of the unfolded protein response (UPR). The UPR also
contributes to the regulation of various intracellular signaling pathways such as calcium
signaling and lipid signaling. More recently, the mitochondria-associated ER membrane
(MAM), which is a site of close contact between the ER and mitochondria, has been
shown to function as a platform for various intracellular stress responses including
apoptotic signaling, inflammatory signaling, the autophagic response, and the UPR.
Interestingly, in cancer, these signaling pathways from the ER are often dysregulated,
contributing to cancer cell metabolism. Thus, the signaling pathway from the ER may be
a novel therapeutic target for various cancers. In this review, we discuss recent research
on the roles of stress responses from the ER, including the MAM.
Keywords: endoplasmic reticulum, mitochondria-associated ERmembrane, unfolded protein response, ER stress,
cancer
Introduction
In eukaryotic cells, the endoplasmic reticulum (ER) is an organelle that extends throughout the
cytoplasm as a vast membranous network. The shape of the ER reflects its many cellular functions,
which include folding newly synthesized proteins, calciumhomeostasis, and phospholipid synthesis,
leading to the regulation of various intracellular signaling pathways (1–6). In particular, as a
central platform of protein quality control, the ER contributes to adaptation to adverse synthetic,
metabolic, and other conditions. When the integrity of the ER is perturbed by adverse conditions,
unfolded/misfolded proteins accumulate in the ER lumen, a condition called ER stress, which in
turn activates the unfolded protein response (UPR) (7, 8). Furthermore, some reports have suggested
that perturbation of calcium homeostasis and dysregulation of lipid metabolism are also involved in
activation of the UPR (9–14). UPR signaling consists of three major stress sensors that reside on the
ER membrane: RNA-dependent protein kinase-like kinase (PERK), activating transcription factor
6 (ATF6), and inositol-requiring enzyme 1α (IRE1α). The roles of these signaling pathways are to
adapt to ER stress through translational attenuation, upregulation of ER chaperones, and protein
degradation (8, 15) (Figure 1). Interestingly, activation of the UPR in cancer cells is sustained by
exposure to various stresses, including hypoxia, oxidative stress, and nutrient starvation. Therefore,
it is currently believed that the UPR may play critical roles in tumor progression, metastasis,
tumorigenesis, and survival (16–18).
It has been observed that approximately 5–20% of the mitochondrial surface directly con-
tacts the ER (19, 20). This site of close contact between the ER and mitochondria is called the
mitochondria-associated ER membrane (MAM) and is formed by several molecular bridges. The
mitochondrial outer membrane proteins mitofusin 1 and 2 (MFN1 and MFN2) are required
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FIGURE 1 | The UPR signaling pathway. Membrane and secretory
proteins are synthesized by the rER and translocated into the ER lumen.
Activated PERK phosphorylates eIF2α and causes general translational
attenuation. The PERK-eIF2α pathway selectively induces expression of the
transcription factor ATF4. Activated IRE1α undergoes dimerization and
oligomerization, splices an intron from the XBP1 mRNA and produces the
transcription factor XBP1s. IRE1α can also induce mRNA degradation.
Activated ATF6 translocates to the Golgi and is sequentially cleaved
by the Golgi-resident site-1 and site-2 proteases, thereby releasing
cleaved ATF6.
for mitochondrial fusion. MFN1 contributes to mitochon-
drial docking and fusion, whereas MFN2 stabilizes associations
between mitochondria. This maintenance of mitochondrial mor-
phology is regulated by hetero-oligomeric MFN complexes
on the mitochondrial outer membrane. Interestingly, MFN2
is also located on the ER membrane and forms homotypic
or heterotypic complexes with mitochondrial MFNs, result-
ing in an interaction between the ER and mitochondria (21)
(Figure 2). Acting as a similar molecular bridge, the inosi-
tol triphosphate receptor (IP3R) on the ER indirectly inter-
acts with the mitochondrial outer membrane-resident voltage-
dependent anion channel 1 (VDAC1) via the cytosolic chaperone
glucose-regulated protein 75 (GRP75) (22). In addition, recent
reports have demonstrated that the B-cell receptor-associated
protein 31 (Bap31)-mitochondrial Fission-1 homolog (Fis1) com-
plex (23) and vesicle-associated membrane protein-associated
protein B (VAPB)-protein-tyrosine phosphatase interacting pro-
tein 51 (PTPIP51) complex act as tethering complexes for the
ER-mitochondrion bridge (24) (Figure 2).
The MAM is crucial for the regulation of numerous cellular
functions including lipid trafficking (25–27), calcium cycling (28,
29), and energy metabolism (30). This subdomain of the ER also
directly contributes to biogenesis through the synthesis of phos-
pholipids and sphingolipids, the levels of which are enriched at the
MAM(25, 31–35). Interestingly,most cancer cells show character-
istic alterations in de novo lipid biosynthesis, lipogenic phenotype,
and lipid metabolism (36, 37). Therefore, current reports have
considered that lipogenesis- and lipolysis-related pathways are
involved in tumorigenesis, migration, invasion, and survival (36–
38). TheMAMhas also been shown to act as a platform for various
intracellular signaling pathways, including oncogenic signaling
(39–41). Although several groups have addressed the pathophysi-
ological relevance between the MAM and diseases, the role of the
MAM, especially in cancer, has not been clearly elucidated. In this
review, wewill summarize some emerging roles of stress responses
from the ER, particularly from theMAM, and discuss whether the
MAMmight be a potential therapeutic target in cancer.
Signaling Pathways from the ER
Endoplasmic reticulum stress activates the UPR, which is the
most thoroughly characterized stress signaling pathway from the
ER. The UPR also plays important roles in tumor development
and tumor growth through adaptation to microenvironments. In
cancer cells, the UPR is constitutively activated because abnormal
cell proliferation requires elevated protein synthesis during tumor
development and tumor growth (42, 43). In addition, cancer
cells are exposed to various stresses such as hypoxia, low glu-
cose, low pH, and nutrient starvation, which are well known to
induce the UPR (42–45). Recent research in oncology indicates
that these microenvironmental challenges are associated with the
constitutive activation of the UPR. Additionally, the perturba-
tion of calcium homeostasis in cancer cells is correlated with
their abnormal phenotypes, including sustained cell proliferation
and avoidance of cell death, through the remodeling of calcium
signaling (46–48). Furthermore, cancer cells undergo changes in
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FIGURE 2 | ER-mitochondrion tethering. In mammalian cells, four types of
molecular bridges for ER-mitochondrion tethering have been identified.
ER-resident MFN2 interacts with mitochondrial MFN1 and MFN2. The ER
calcium channel IP3R associates with the mitochondrial calcium channel VDAC1
through GRP75. The ER protein Bap31 connects with the mitochondrial protein
Fis1. The ER protein VAPB interacts with the mitochondrial protein PTPIP51.
Indicated MAM-resident proteins and complexes regulate various signaling
pathway from MAM as described in figure.
lipid metabolism via the dysregulation of lipogenic and lipolytic
enzymes, leading to lipid stress signaling. This is closely correlated
with tumorigenesis, malignancy, and growth (36–38). Abnormal-
ities in calcium homeostasis and lipid metabolism directly trigger
ER stress (9–14). This section focuses on the cancer-related roles
of the ER stress signaling pathways, including UPR signaling,
calcium signaling, and lipid signaling.
The UPR
Unfolded protein response signaling is mediated by three major
transmembrane transducers: PERK, ATF6, and IRE1α (Figure 1).
These sensors are maintained in an inactive state by binding to
an ER chaperone, the 78 kDa glucose-regulated protein (GRP78),
which is known as a master regulator of the UPR. During ER
stress, GRP78 dissociates from sensor proteins in response to
the accumulation of unfolded/misfolded proteins and reduced
ER calcium content, resulting in the activation of distinct UPR
signaling branches (8, 13, 49).
The PERK Branch
Protein kinase-like kinase is an ER type I transmembrane kinase
that has a PEK-like catalytic domain in its cytosolic C-terminal
region. The activated PERK pathway phosphorylates eukaryotic
translation initiation factor 2α (eIF2α) and leads to the inhibition
of protein translation into the ER (8, 15, 50). In addition, phospho-
rylation of eIF2α selectively induces the expression of activating
transcription factor 4 (ATF4), thereby inducing growth arrest and
upregulating UPR genes including CCAAT/enhancer-binding
protein-homologous protein (CHOP), ER oxidoreductase 1α, and
several pro-apoptotic factors (8, 15). Phosphorylation of eIF2α is
also induced by multiple kinases, including protein kinase R, gen-
eral control non-repressed 2, and haem-regulated eIF2α kinase.
eIF2α phosphorylation-related signaling is described as the inte-
grated stress response (ISR) (43, 51–53). The ISR is activated in
response to various stresses, including amino acid starvation, viral
infection, and haem deficiencies, in addition to ER stress. PERK
also directly phosphorylates transcription factor NF-E2-related
factor 2 (Nrf2), which is known to have the dual role in cancer,
tumor suppressor function and oncogenic function (54). Under
unstressed condition,Nrf2maintains the inactive state in the cyto-
plasm through interactionwith kelch-like ECH-associated protein
1. PhosphorylatedNrf2 byPERKdissociates fromkelch-like ECH-
associated protein 1, resulting in translocation into the nucleus
and expression of antioxidant genes (55, 56). However, artificial
activation of PERKmainly induces ISR signaling target genes in an
eIF2α phosphorylation-dependent manner (57). Although PERK
is activated by not only ER stress but also other stress (e.g., glucose
starvation and oxidative stress), PERK-mediated Nrf2 activation
may be limited to the ER stress condition.
Most cancers are constitutively exposed to various stresses,
including hypoxia and nutrient deprivation, even when glycolysis
and angiogenesis are promoted in cancer cells (42–45). Activation
of PERK signaling and the ISR are considered necessary for tumor
survival during hypoxia and nutrient starvation (43). Hypoxia
and oxidative stress increase the generation of reactive oxygen
species (ROS). In addition, ER oxidoreductase 1α, which regulates
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ER redox status, is upregulated through PERK signaling in the
ISR (58–60). Consistent with the enhanced production of ROS in
tumors, the expression of ER oxidoreductase 1α is substantially
increased in various types of cancers (61). The ablation of PERK
signaling or the ISR leads to ROS production and thereby impairs
tumor growth through oxidative DNAdamage (62). Furthermore,
the ISR,which inducesATF4 expression, is also required for tumor
survival and growth. Suppression of ATF4 expression inhibits
tumor survival and proliferation in response to both amino acid
deprivation and glucose deprivation (63, 64). Taken together, can-
cer cells adapt to hypoxia, oxidative stress, and nutrient starvation
by improving their PERK- and ISR-mediated redox homeosta-
sis and metabolic homeostasis, respectively. Transcription factor
CHOP, a downstream target of ATF4, induces cell death in
response to the intense and/or prolonged ER stress. Deletion of
CHOP or suppression DNA damage-inducible 34, a downstream
of CHOP, promotes tumor dedifferentiation and survival. Thus,
it is possible that this dual role of the PERK and ISR signaling
pathways might be therapeutic targets for cancer. Indeed, it has
been reported that PERK specific inhibitor GSK2656157 impairs
angiogenesis and amino acid metabolism, resulting in prevention
of tumorigenesis in vivo (65). Furthermore, in leukemic cells, salu-
brinal, a selective inhibitor of eIF2α dephosphorylation induces
synergistic apoptosis under proteasome inhibitor-induced ER
stress condition (66). These observations strongly suggest that the
compounds, which regulate PERK pathway, may shed light on the
treatment of cancer.
The IRE1α Branch
Inositol-requiring enzyme 1α is an ER type I transmembrane
endoribonuclease/kinase protein that contains a kinase domain
and an endoribonuclease domain in its cytosolic C-terminal
region. During ER stress, activated IRE1α catalyzes the splicing of
a 26-nt intron from themRNAofX-box binding protein 1 (XBP1),
resulting in the production of active XBP1 (XBP1s) transcription
factor and the consequent promotion of ER-associated degrada-
tion (8, 15). IRE1α also cleaves non-specific mRNAs through a
process termed regulated IRE1α-dependentmRNAdecay (RIDD)
(8, 15, 67, 68). Several reports have indicated that the IRE1α
signaling, especially via the IRE1α-XBP1 pathway, is required
for tumor growth and survival during hypoxia. For example,
XBP1-deficient cells are vulnerable to hypoxia-induced apoptosis,
leading to the impairment of hypoxic growth in tumor xenografts
(18). A recent report suggests that expression of the spliced formof
XBP1s is essential for tumor angiogenesis independently of vascu-
lar endothelial growth factor, a well-known angiogenic factor (69).
XBP1s is constitutively activated through the hypoxia-inducible
factor-1α pathway in response to hypoxia, resulting in tumor
development (70). In addition, a recent analysis indicated that the
IRE1α-RIDD pathway contributes to tumor growth, infiltration,
and invasion under tumor microenvironment conditions (71).
Inositol-requiring enzyme 1α also induces activation of c-Jun
N-terminal kinase (JNK) through interaction with tumor necrosis
associated factor 2 and apoptosis signaling-regulating kinase 1
(72, 73). IRE1α-JNK pathway contributes to not only apoptotic
cell death (72) but also cell survival via c-Jun activation (74, 75),
suggesting that IRE1α-JNK pathway has binary effects on cell
fate. In neuroblastoma, IRE1α-JNK pathway induced by severe
ER stress triggers apoptosis (76). On the other hand, IRE1α-JNK
pathway involves in induction of autophagy, which protect cancer
cell death (77). Thus, it is considered that IRE1α signaling con-
tributes to both tumor survival and cell death in some situations
of chronic stress. Since activities of kinase and endoribonuclease
of IRE1α can be selectively controlled by distinct classes of adeno-
sine triphosphate (ATP)-competitive inhibitors (78), it is expected
that regulation of pathway might be a therapeutic strategy for
cancer.
Endoplasmic reticulum stress activates T cells in the adaptive
immune system in tumor (79). IRE1α signaling phosphorylates
IκB kinase and activates NF-κB pathway, leading to induction of
inflammatory response (80). Pro-inflammatory cytokines inter-
leukin (IL)-6 and tumor necrosis factor-α are induced byXBP1s in
response to ER stress (81, 82). In macrophages, activation of UPR
is triggered by culture media conditioned by ER stressor-treated
cancer cells via toll-like receptor, suggesting that cancer cells
non-cell-autonomously induce tumor inflammation through the
transmission of UPR signaling to macrophages (83). Recent study
has shown that loss of ER chaperone calreticulin results in the
prevention of phagocytosis and antigen presentation in dendritic
cells, and translocation of calreticulin to the plasma membrane
induced by anti-neoplastic drugs anthracycline triggers tumor
immunogenicity (84). Although anti-tumor agent cisplatin has no
effect on induction of an anti-cancer immune response via the
UPR activation, the combination of ER stress inducer (e.g., thap-
sigargin or tunicamycin) with cisplatin triggers translocation of
calreticulin to the plasma membrane and trigger tumor immuno-
genicity (85). Thus, it is possibility that combination of anti-tumor
drugs and ER stress inducers might become therapeutic strategies
for various cancers.
The ATF6 Branch
Activating transcription factor 6 is an ER type II transmembrane
protein that possesses a transcriptional activation domain in its
cytosolic region. Upon ER stress, ATF6 is transported from the
ER membrane to the Golgi, where it is sequentially cleaved by
the Golgi-resident site-1 and site-2 proteases. The cleaved ATF6
is translocated into the nucleus and binds to ER stress elements
and UPR elements, leading to the expression of UPR target genes
such as ER chaperones (8, 15). Expression of GRP78, which is
upregulated by the ATF6 signaling during ER stress, has been
shown to be essential for tumor growth, survival, progression, and
metastasis (86–88). Conversely, overexpression of GRP78 sup-
presses non-steroidal anti-inflammatory drug-induced apoptosis
in cancer cells (86). Therefore, both ATF6 signaling and GRP78
appear to contribute to tumor adaptation to microenvironmental
challenges by promoting protein folding.
Calcium Signaling from the ER
The ER is a major intracellular calcium store. Calcium con-
tributes to a wide variety of intracellular signaling pathways as
a second messenger (48, 89). However, depletion of calcium in
the ER disturbs the function of ER chaperones and induces ER
stress, leading to activation of the UPR (11, 13, 14). In addition,
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increasing intracellular calcium concentrations triggers cytotox-
icity under certain conditions such as increased ROS generation
(48). Thus, both cytosolic calcium and the concentration of cal-
cium in the ER must be tightly regulated. Import of calcium
into the ER is maintained by sarcoplasmic/ER calcium ATPase
(SERCA) pumps, which function against a calcium concentration
gradient (90). Conversely, ER-resident calcium is released through
two tetrameric calcium channels, ryanodine receptors and inositol
1,4,5-trisphosphate receptors (IP3Rs) (91–93). These mediators
are involved in protein synthesis, gene expression, secretion, the
cell cycle, cell proliferation, and differentiation through the reg-
ulation of calcium signaling (48, 89, 94). Surprisingly, in most
cancers, the calcium concentration in the ER is decreased, whereas
the cytosolic calcium concentration is increased (47, 48). This
indicates that various cancers alter the activity or expression of
SERCA pumps and IP3Rs, resulting in the remodeling of calcium
signaling. Because abnormal intracellular calcium homeostasis
occurs via altered activity or expression of ER-resident calcium
pumps and channels in cancer, regulation of the ER-resident
calcium status may be a candidate for the treatment of cancer.
Role of SERCA Pumps in the Remodeling of
Calcium Signaling
Sarcoplasmic/ER calcium ATPase pumps, which are type P
ATPase pumps, import calcium into the ER from the cytosol
to regulate the cytosolic calcium level. They have diverged into
three different genes and are further composed of at least five
isoforms (SERCA1a, 1b, 2a, 2b, and 3). Among the SERCApumps,
SERCA2b is ubiquitously expressed and has the highest calcium
affinity (29, 90, 95–97). Phospholamban and sarcolipin have been
reported to be endogenous negative regulators that suppress the
affinity of SERCA pumps for calcium (98). Furthermore, the
activity of SERCA pumps is also regulated by post-translational
modifications including SUMOylation, glutathiolation, and nitra-
tion (99–101). Several reports have shown that the expression of
SERCA pumps, especially SERCA2b and SERCA3, is frequently
decreased in cancer cells. Korosec et al. and Endo et al. reported
that in colon, lung, and oral cancer, SERCA2b expression was
reduced by alterations of the promoter region or by an epige-
netic mechanism as an early event in tumorigenesis (102, 103).
Although the mechanism remains unclear, the ATPase activity of
SERCA2b is also reduced in advanced tumorigenic thyroid cells,
consistent with the reductions at the mRNA and protein levels
(104). Furthermore, germline alterations in SERCA2b have been
indicated as closely involved in the early phase of carcinogenesis
in the colon and lung (102). Similar to SERCA2b, SERCA3 is also
reduced in colon and gastric cancer cells (105, 106). In addition,
SERCA3 expression is involved in the remodeling of intracellular
calcium homeostasis during cell differentiation (105).
Role of IP3Rs in the Remodeling of Calcium
Signaling
Inositol triphosphate receptors are ER-resident calcium channels
that form tetrameric assemblies and thereby release calcium into
the cytosol from the ER. IP3Rs play an important role in calcium
signaling and homeostasis. IP3Rs consist of three subtypes (IP3R1,
IP3R2, and IP3R3) that are differentially expressed in specific
cell types (91, 107, 108). IP3, which is generated via the phos-
pholipase C pathway and is an agonist of IP3Rs, directly binds
to the cytosolic region of all three IP3R subtypes and enhances
calcium release (109, 110). The activity of IP3Rs is also positively
or negatively regulated by endogenous factors including calcium,
ATP, and pH (111, 112). Interestingly, some reports have demon-
strated that kinase and cytosolic proteins can regulate the activity
of IP3Rs (113–115). It is reported that serine/threonine kinase
Akt/protein kinase B phosphorylates IP3Rs, resulting in inhibi-
tion of calcium release activity of IP3Rs (113, 114). In addition,
Bcl-2 family protein BAX and BAK positively regulates calcium
release from the ER through a decrease of IP3Rs phosphoryla-
tion (115).
Recent studies have shown alterations in the activity and
expression of IP3Rsduring various processes of tumor cells includ-
ing survival, growth, proliferation, invasion, and metastasis (116–
127). In breast cancer cells, activation of IP3Rs, especially IP3R3, is
enhanced by ATP, thereby promoting cell growth through regula-
tion of the spatiotemporal pattern of intracellular calcium (116–
119). Moreover, enhanced expression of IP3R1 and IP3R3 is also
involved in the epithelial-mesenchymal transition (EMT) of breast
cancer (117, 120). In addition to breast cancer, IP3R3 is specifically
overexpressed in gastric cancer cells (121). Inhibition of IP3R3 by
an antagonist of IP3Rs attenuates their proliferation and induces
apoptosis (121). Additionally, although the IP3R subtype remains
unclear, colorectal cancer (122), lung cancer (123, 124),melanoma
(125), and insulinoma (126, 127) also show enhanced IP3Ractivity
and expression, leading to the remodeling of calcium signaling.
Therefore, IP3Rs might be therapeutic targets for treatment of
cancer.
Lipid Signaling from the ER
The ER can be classically divided into two types, rough ER
(rER) and smooth ER (sER), which have different functions and
morphology (128). The rER is studded with ribosomes on the
membrane surface; it forms a membranous sheet and plays an
important role as a major site of protein synthesis. By contrast,
the sER is ribosome-free and exists as a tubular or reticular
network throughout the cytoplasm (128). A large number of
reports have demonstrated that sER is the site of lipid biogenesis.
Among various lipids and phospholipids, glycerophospholipids
and sphingolipids are essential as major components of biological
membranes, and they are also important as signaling molecules
(129, 130). These signaling lipids play important roles in cellu-
lar processes such as cell proliferation, migration, metabolism,
inflammation, and apoptosis (Figure 3). In addition, both rER
and sER are composed mainly of glycerophospholipids [i.e.,
phosphatidylcholine, phosphatidylethanolamine, phosphatidyli-
nositol (PI), and phosphatidyleserine], and sphingolipids [i.e.,
sphingosine-1-phosphate (S1P) and sphingosine] (130). In these
phospholipids, including both saturated and unsaturated fatty
acids are usually disturbed in cancer cells (36–38). Recent studies
have demonstrated that changing the balance between membrane
phospholipid saturation and unsaturation activates UPR signaling
(10, 12). Furthermore, alterations in fatty acid unsaturation in
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FIGURE 3 | Role of the ER lipid signaling pathway. In the ER,
glycerophospholipids and phosphatidylinositol are synthesized.
Phosphatidylinositol is converted to highly phosphorylated forms. Conversion
of PIP2 to PIP3 is promoted by PI3K, resulting in the regulation of cell
proliferation, cell migration, and cell differentiation through the induction of
PI3K-Akt-mTOR signaling. Sphingosine is also synthesized on the cytosolic
surface of the ER through the de novo biosynthesis of ceramide. Both
ceramide and sphingosine inhibit Akt activity via the activation of PKCδ and
protein phosphatase 2A. Conversely, C1P and S1P antagonize the effects of
ceramide and sphingosine and activate Akt, consequently contributing to cell
survival, cell proliferation, and inflammation. Pro-oncogenesis-related lipids
are indicated in red. Anti-oncogenesis-related lipids are indicated in blue.
membranes are implicated in cancer (131). Based on these find-
ings, it is believed that the UPR-regulated signaling lipids or their
precursors may have important roles in tumorigenesis and in the
maintenance of cancer cell metabolism.
Role of Lipid Signaling via Glycerophospholipids
Glycerophospholipids are glycerol-based phospholipids consist-
ing of a polar group and hydrophobic chains. In general, glyc-
erophospholipids are classified by differences in polar group
(37, 130, 132). Among the glycerophospholipids, phosphatidyl-
choline, phosphatidylethanolamine, and PI are synthesized in the
ER. Glycerol and fatty acids are transformed into phospholipid
precursors, including triglycerides and diacylglycerol phosphate,
by ER-resident enzymes. During the next synthesis step, on
leaflets of the ER membrane, these phospholipid precursors are
dephosphorylated and then converted to phosphatidylcholine or
phosphatidylethanolamine. PI is also synthesized from -myo-
inositol and CDP-diacylglycerol through PI synthase in the ER.
Synthesized PI can be converted to several highly phosphory-
lated forms called phosphoinositides. They are localized mainly
in the plasma membrane and play important roles in various
signaling pathways and vesicle trafficking (49, 130, 132). Among
the various types of phosphoinositides, the plasma membrane-
resident phosphoinositides PI-4,5-bisphosphate [PI(4,5)P2] and
PI-3,4,5-bisphosphate [PI(3,4,5)P3] are specifically involved in
cell growth- and survival-related intracellular signaling (37). In
response to stimulation by growth factors, conversion of PIP2 to
PIP3 is promoted through phosphorylation by the class I phospho-
inositide 3-kinase (PI3K) (37, 133). This conversion is transient
and dramatic, and it enhances the binding of Akt to PI(3,4,5)P3,
and thereby to phosphorylated Akt, resulting in activation of
important cascades, including mammalian target of rapamycin
(mTOR) signaling (133, 134) (Figure 3). mTOR signaling is an
oncogenic PI3K pathway that regulates protein synthesis, cell pro-
liferation, migration, differentiation, and the cell cycle (134–137).
Conversion of PI(3,4,5)P3 to PI(4,5)P2 occurs through dephos-
phorylation via the phospholipid phosphatase PTEN and is antag-
onized by PI3K pathway (138, 139). Thus, cellular functions are
maintained through a physiological balance of phosphorylation
and dephosphorylation by PI3K and PTEN, respectively. Interest-
ingly, several cancers frequently show constitutively active PI3K
mutations or loss-of-function mutations in PTEN, resulting in an
increase in PI(3,4,5)P3 that in turn contributes to oncogenesis (37,
140, 141). These mutations are particularly observed in ovarian,
colon, breast, and gastric cancer (142). Although the amount of
additional PI, a precursor of PI(4,5)P2 and PI(3,4,5)3, remains
poorly understood, PI3K, Akt, and mTOR may be therapeutic
targets for various cancers.
Role of Lipid Signaling via Sphingolipids
Sphingolipids are sphingoid-based phospholipids that are
produced through the de novo biosynthesis of ceramide, which
is generated by a condensation reaction involving serine and
palmitoyl-CoA via serine palmitoyl transferase (37, 107, 109).
This biosynthesis occurs on the cytosolic surface of the ER. Then,
ceramide is coordinated by various enzymes, including ceramide
kinase, glucosylceramide synthase, galactosyltransferase,
sphingomyelin synthase, and ceramidase, consequently
producing ceramide 1-phosphate (C1P), glycosphingolipids,
sulphatide, sphingomyelin, sphingosine, and S1P. Conversely,
ceramide is synthesized from these products via several metabolic
pathways (37, 107, 109). Among sphingolipids, ceramide, C1P,
sphingosine and S1P are potent signaling molecules and have
important roles in cellular processes. Ceramide and sphingosine
are involved in anti-oncogenic processes such as apoptosis,
cell-cycle arrest, and cellular senescence (37, 143–146) (Figure 3).
By contrast, C1P and S1P antagonize the pro-apoptotic effects
of ceramide and sphingosine and contribute to survival,
proliferation, and inflammation (37, 38, 143–145). Ceramide
and sphingosine can attenuate Akt activity (37, 38); they directly
activate PKCδ, which inhibits the translocation of Akt to the
plasma membrane, leading to suppression of Akt activity. As
another inhibitory mechanism, ceramide dephosphorylates Akt
through the activation of cytosolic protein phosphatase 2A. By
contrast, C1P and S1P are positive regulators of the Akt signaling
pathway via activation of PI3K (37, 143, 146). Interestingly, S1P
is linked to endothelial growth factor-, platelet-derived growth
factor-, and transforming growth factor β-related signaling
pathways (146–148). Consequently, Akt, ERK1/2, and PKC-β
are activated by crosstalk between S1P and growth factors.
Surprisingly, it has been reported that several sphingolipid
synthases and metabolites are dysregulated in many types of
cancer. Especially in leukemia, melanoma, breast, ovarian, and
colon cancers, sphingosine kinase is substantially upregulated,
resulting in increased generation of S1P (149–155). Conversely,
the production of ceramide is suppressed by increased ceramide
kinase in liver and breast cancer (156, 157). Furthermore, in
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the de novo biogenesis of ceramide, the expression of serine
palmitoyl transferase, which is localized on the surface of the
ER, is decreased (149). Based on these findings, it is possible
that cancers evade the anti-oncogenic effects of sphingolipids
via the dysregulation of sphingolipid metabolism including the
upregulation of anti-apoptotic sphingolipids.
Signaling Pathways from the MAM
As noted above, in addition to the rER and sER, recent reports
have defined a subdomain of the ER that is a site of direct
communication between the ER and mitochondria, called the
MAM (49). It is believed that this tether is important for lipid
and calcium trafficking between the ER and mitochondria to
regulate lipid metabolism and mitochondrial calcium home-
ostasis (25–30, 49). Several proteins involved in lipid synthesis
and trafficking are enriched at the MAM. Acyl-CoA synthase
4, acyl-CoA cholesterol acyl transferase 1, phosphatidyl serine
synthase, phosphatidylethanolamine N-methyltransferase 2, and
acyl-CoA:diacylglycerol acyltransferase 2 have been identified
as MAM-enriched enzymes (25, 32–35). Among these enzymes,
acyl-CoA synthase 4 is well known as a marker protein of the
MAM. Furthermore, it has also been reported that the MAM is
important for the de novo biogenesis of phospholipids and for
their transport between the ER and mitochondria (25, 32–35).
At the MAM, IP3R binds to the outer-mitochondrial-membrane-
localized calcium channel VDAC1 via the cytosolic chaperone
GRP75, leading to the transfer of calcium to the mitochondrion
(22). Furthermore, the ER chaperone sigma-1 receptor is also
localized in theMAMand can interact with IP3R (158). This inter-
action is related to the stability of IP3R and sustains the calcium
transfer from the ER to the mitochondria. SERCA2b is also local-
ized at the MAM and regulates the import of calcium into the ER
(159). More recently, in addition to proteins involved in lipid and
calcium trafficking, a variety ofMAM-resident proteins, including
proteins related to oncogenic signaling, have been characterized
(Figure 2; Table 1).
Apoptotic Signaling Pathway at the MAM
Mitochondria are intracellular power plants that produceATP and
many biosynthetic intermediates while also contributing to the
metabolism of amino acids and lipids and to the maintenance
of intracellular calcium homeostasis (160–164). Mitochondria
also have non-canonical functions such as the induction and
amplification of apoptotic cell death (165, 166). Interestingly,
recent reports have shown that the MAM functions in the apop-
totic signaling pathway through dysregulation of calcium transfer
from the ER to mitochondria. Mitochondrial calcium uptake is
enhanced during apoptosis. Promyelocytic leukemia (PML) pro-
tein, which is involved in calcium homeostasis and apoptosis, is
localized at the MAM and functions there (167). PML normally
forms complexes with IP3Rs, Akt, and protein phosphatase 2,
resulting in a reduction in the hyper-phosphorylation of IP3R3,
which in turn results in mitochondrial calcium overload through
an increase in calcium release from the ER (167). Interestingly,
PML is often decreased or dysregulated in cancer cells, leading to
an escape from mitochondrial calcium-mediated apoptosis (168,
169). Thus, it is considered that MAM-resident PML is involved
in anti-oncogenesis and is a tumor suppressor.
Another MAM-resident protein involved in apoptosis, the
truncated form of the SERCA (S1T), has been shown to
induce pro-apoptoticmitochondrial calciumoverload (170). High
expression of S1T increases basal mitochondrial calcium and trig-
gers abnormal mitochondrial structure and function, resulting in
apoptotic cell death. S1T knockdown results in an impairment
of mitochondrial calcium overload-induced apoptosis. Moreover,
S1T has been shown to be involved in ER stress (170). Taken
together, it is possible that S1T is important for cell fate through
ER-mitochondrion calcium transfer-induced ER stress.
TABLE 1 |MAM-resident proteins associated with a variety of signaling pathways and cancers.
Functional role Key MAM proteins
or complexes
Specific effect Expectation of pro-
or anti-oncogenesis
Reference
Apoptotic signaling PML Involvement with calcium homeostasis and
mitochondrial calcium overload
Anti (167)
S1T Induction of mitochondrial calcium
overload-induced apoptosis
Anti (170)
PTEN Enhancement of ER-mitochondria calcium
transfer though regulation of IP3R
Anti (171)
Inflammation signaling NLRP3 NLRP3 inflammasome forms at the MAM upon
NLRP3 activation
Anti (174)
Antiviral innate immune response MAVS-RIG-I The MAVS-RIG-I signaling induces from the MAM
during virus infection
Anti (183)
Autophagic signaling Atg14L Essential for the origin of autophagosome
membrane
Anti (190)
Cellular metabolism-related signaling mTORC2 MAM-resident mTORC2 controls the MAM
integrity and mitochondrial functions
Pro (194)
UPR signaling PERK PERK plays a role of in ER-mitochondria tethering Pro (186)
MFN2 MFN2 can be interacts with PERK and regulates
PERK-mediated UPR
Pro (187)
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PTEN dephosphorylates PI(3,4,5)P3, converting it to PI(4,5)P2,
thereby attenuating the oncogenic PI3K signaling cascade (138,
139). Thus, PTEN has been considered a tumor suppressor pro-
tein. Interestingly, some PTEN proteins are localized at the MAM
and function in calcium transfer from the ER tomitochondria and
in pro-apoptotic mitochondrial calcium overload (171). PTEN
knockdown impairs calcium release from the ER, decreases the
cytosolic and mitochondrial calcium levels, and thereby reduces
cytochrome C release and caspase 3 cleavage. These results indi-
cate that ablation of PTEN attenuates calcium-dependent apop-
totic cell death. By contrast, overexpression of a specific chimeric
PTEN that is localized at the cytoplasmic surface of the ER
membrane enhances ER-mitochondrion calcium transfer and the
vulnerability of cells to arachidonic acid-induced apoptosis. This
effect of PTEN is dependent on IP3R function. PTEN interacts
with IP3Rs, thereby inhibiting their hyper-phosphorylation and
consequently increasing calcium release from the ER. Surpris-
ingly, the protein phosphatase activity of MAM-resident PTEN is
independent of its lipid phosphatase activity (171). Based on these
findings, PTEN is thought to prevent oncogenic signaling through
its canonical and non-canonical activities.
Inflammatory Signaling Pathway at
the MAM
Inflammasomes are important large multiprotein complexes of
the innate immune system that act as molecular platforms for
immune defenses against microbial-, viral infection- and stress-
mediated cellular danger signals via maturation or release of pro-
inflammatory cytokines including IL-1β and IL-18 (172, 173).
The components and mechanism of activation of the NOD-like
receptor family pyrin domain-containing 3 (NLRP3) inflamma-
some have been particularly well analyzed (172, 173). In response
to microbial stress, NLRP3 becomes oligomerized prior to its
activation. It interacts with apoptosis-associated speck-like pro-
tein containing a CARD (ASC) and recruits procaspase-1, which
in turn is converted to active caspase-1, leading to the gen-
eration of mature IL-1β (172, 173). NLRP3 protein has been
reported to be enriched both in the ER and at the MAM (174).
In addition, NLRP3 is co-localized with ASC proteins at the
MAM when NLRP3 is activated by stimulation with nigericin or
monosodium urate, which are known as inflammasome inducers.
Thus, the NLRP3 inflammasome may be formed at the MAM.
The detailed mechanisms, such as how and why the NLRP3
inflammasome is localized at the MAM, remain unclear. How-
ever, it has been reported that ROS generation from damaged
mitochondria is required for NLRP3 inflammasome activation
(174). There is a possibility that NLRP3 at the MAM senses
mitochondrial function. The role of inflammasomes includes not
only immune responses but also cancer pathogenesis. In vari-
ous cancers, the NLRP3 inflammasome has been shown to be
involved in the prevention of tumorigenesis, malignancy, and
growth (175). NLRP3 /  mice exhibit tumors of increased mass,
number, and size. The deletion of the NLRP3 inflammasome
components ASC and caspase-1 produces a similar phenotype.
These findings indicate that the NLRP3 inflammasome has anti-
tumor functions (175). Furthermore, it has been reported that
NLRP3 inflammasome components, including NLRP3, ASC, and
procaspase-1, are downregulated in hepatocellular carcinoma
(HCC) (176). This downregulation is dependent on a decrease in
their mRNA levels. Interestingly, the expression pattern of NLRP3
inflammasome components changes dynamically in the develop-
ment stage of hepatocarcinogenesis. Although the components of
theNLRP3 inflammasome components are expressed at low levels
in the healthy liver, they are upregulated in hepatitis and hepatic
cirrhosis. However, their expression levels substantially decrease
during hepatocarcinoma development. From these findings, this
report concluded that dynamic regulation of the expression of
NLRP3 inflammasome components is required for HCC devel-
opment and progression. TheMAMmay be a central platform for
NLRP3 inflammasome-mediated anti-tumorigenic functions.
Antiviral Innate Immune Response at
the MAM
Retinoic acid-inducible gene I (RIG-I) is a cytosolic pathogen re-
cognition receptor that contributes to the innate immune response
against viral infection via its adaptor proteinmitochondrial antivi-
ral signaling (MAVS) (177, 178). RIG-I-MAVS signaling triggers
the production of type I IFN and pro-inflammatory cytokines
and results in interference with viral replication (177, 178). Viral
RNA genome fragments trigger apoptotic cell death in cancer
cells through the pro-apoptotic protein, TNF-related apoptosis-
including ligand and NOXA, which are induced by RIG-I-MAVS
signaling (179). The RIG-MAVS signaling pathway is believed
to function in the cellular antitumor immune response (180).
Some groups have reported that MAVS can be localized to the
mitochondria or peroxisomes (181, 182). The main localization
site of MAVS has been shown to be the MAM (183). Moreover,
RIG-1 is recruited to the MAM-resident MAVS upon virus infec-
tion, leading to the activation of RIG-I-MAVS signaling (183).
When the formation of the MAM is inhibited by MFN2 knock-
down, MAVS localization increases at the peroxisomes, resulting
in the enhancement of IFN-β promoter activity via RIG-I-MAVS
signaling. These results suggest that the MAM can regulate the
localization and signaling of MAVS. Surprisingly, when cells are
infectedwith hepatitis C virus,NS3/4Aprotease selectively cleaves
theMAM-residentMAVS to avoid the antiviral response. Because
cleaved MAVS does not have antiviral activity, it suppresses IFN-
β promoter activity. The MAM may function as a platform for
innate immune signaling.
Role of UPR Proteins at the MAM
Several UPR-related proteins, including ER chaperones, calcium
channels, and ER-resident oxidoreductase, have been shown to
reside at the MAM (159, 184, 185). MAM-resident PERK has
been shown to possess heterogeneous roles. For example, PERK
is important for the maintenance of the MAM and triggers ROS-
mediated mitochondrial apoptosis (186). PERK deficiency leads
to ER fragmentation and aberrant calcium release. This func-
tional change of the ER requires defective MAM formation due to
PERK deletion. Interestingly, transient transfection with a kinase-
dead PERK mutant can reconstitute the formation of the MAM,
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indicating that the role of PERK in MAM formation is inde-
pendent of its kinase activity. Furthermore, this PERK function
is involved in mitochondrial sensitization during ROS-mediated
stress and induces ROS-mediated apoptosis. PERK has been
shown to interact directly with MFN2, which forms a molecular
bridge between the ER and mitochondria (187). MFN2 deletion
induces ER stress and activates the three branches of UPR signal-
ing; the PERK, ATF6, and IRE1α pathways (187). Although UPR
signaling mediates the pro-apoptotic pathway under prolonged
ER stress conditions, MFN2 deletion results in the inhibition
of ER stress-induced apoptosis. This MFN2-mediated apoptosis
requires PERK. Furthermore, when PERK is deleted in MFN2-
deleted cells, ROS production and mitochondrial calcium over-
load are reduced, and mitochondrial morphology is improved.
Therefore, in addition to its role in the UPR, PERK is involved in
the regulation of mitochondrial morphology and function. Based
on these reports, it is believed that PERK has multiple functions
through its canonical and non-canonical activities both in the ER
and at the MAM. Although the role of MAM-resident PERK in
oncogenesis remains unclear, it is known that PERK is involved
in the adaptation of cancer cells to tumor microenvironmental
challenges. Thus, it is possible that MAM-resident PERK also
has a pathological function and might be a therapeutic target in
cancer.
Role of the MAM in the Autophagic
Signaling Pathway
Autophagy is one of the proteolytic systems that contribute to
the lysosome-mediated degradation pathway required for main-
taining intracellular homeostasis (188). Defects in autophagy
result in enhanced tumorigenesis, suggesting that this system
plays an important role in tumor suppression (189). Autophagy
is tightly regulated by a set of autophagy-related proteins (Atgs)
that mediate the formation of autophagosomes (188). Autophagy
requires two ubiquitin-like conjugation systems mediated by the
covalent binding of Atg12 to Atg5 and a linkage between LC3 and
phosphatidylethanolamine. The Atg12–Atg5 conjugate interacts
with Atg16 and organizes a non-covalent multimeric complex. It
localizes in nascent autophagosomes and functions as an E3 ligase
of LC3, resulting in autophagosome formation. More recently, the
MAM has been discovered to be the origin of autophagosome
formation (190). Among the many Atg proteins, Atg14L, which
is well known as a pre-autophagosome marker, re-localizes to
the MAM during starvation, and Atg5 then localizes to the same
site during autophagosome formation. Furthermore, in terms of
the mechanism of autophagosome formation at the MAM, it
has been reported that MAM-resident Atg14L interacts with the
ER-resident SNARE protein syntaxin 17. Although the detailed
mechanism of autophagosomal membrane generation is poorly
understood, this event may be regulated via the coordination of
MAM-resident proteins.
Cellular Metabolism-Related Signaling
Pathway at the MAM
Mammalian target of rapamycin plays an important role in
the regulation of various cellular processes (134). It forms two
functionally distinct multi-protein complexes, mTOR complex
1 (mTORC1) and mTORC2 (135, 191). mTORC1 is composed
of mTOR, Raptor, mLST8, and DEPTOR, and it is sensitive to
rapamycin. This complex contributes to the regulation of pro-
tein synthesis and cell growth (134, 135, 191, 192). mTORC2
is composed of mTOR, Rictor, Sin1 mLST8, and DEPTOR, and
it regulates AGC subfamily kinases such as Akt and conse-
quently controls cell growth, cell proliferation, cell spreading,
and organization of the actin cytoskeleton (134, 135, 191, 193).
Furthermore, in addition to these roles, mTORC2 contributes
FIGURE 4 | Roles of signaling pathways from the ER and MAM in cancer.
Cancer cells are constitutively exposed to microenvironmental challenges,
resulting in the remodeling of signaling pathways from the ER and MAM.
Dysregulation of these signaling pathways directly or indirectly contributes to
tumorigenesis and the maintenance of cancer cell metabolism. Thus, these
pathways may lead to novel therapeutic strategies for various cancers.
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to cell survival, cell metabolism, and cell migration in cancer
(193). Thus, mTORC2 is considered a key regulator of cancer
metabolic reprograming, including glycolytic metabolism, lipid
metabolism, glutamine metabolism, and ROS metabolism, for
protection against microenvironmental challenges (193). Interest-
ingly, a recent report has shown that mTORC2 is localized to the
MAM during growth factor stimulation (194).
Mitochondria-associated ERmembrane-residentmTORC2 can
interact with the IP3R-GRP75-VDAC1 complex, which is amolec-
ular bridge at the MAM. Defective mTORC2 results in a decrease
of the ER-mitochondrion contact site, producing mitochondrial
dysfunction including abnormal ATP production and mitochon-
drial calcium overload.Mechanistically, mTORC2 phosphorylates
IP3Rs, hexokinase 2, and phosphofurin acidic cluster sorting pro-
tein 2 through the phosphorylation of Akt. The phosphorylation
of these molecules mediates mitochondrial functions and the
integrity of the MAM. Furthermore, activation of the mTORC2-
Akt-HK2 pathway at the MAM is involved in energy metabolism
and cell survival. Thus, in addition to the canonical roles of
mTORC2, MAM-resident mTORC2 may control mitochondrial
function and cellular metabolism.
Conclusion
The ER extends throughout the cytoplasm and has heterogeneous
morphology and various functions. In addition to newly syn-
thesized protein folding, calcium homeostasis, and phospholipid
synthesis, the ER is a platform for various intracellular signaling
pathways. The current understanding of these signaling pathways
suggests that multiple functions of the ER are relevant to cancer
pathogenesis. The signaling pathways from the ER contribute not
only to oncogenesis but also to tumor suppression. TheUPR iswell
known to contribute to the adaptation to tumor microenviron-
mental challenges through its constitutive activation (Figure 4).
Furthermore, the maintenance of calcium homeostasis in can-
cer cells is critical for tumorigenesis and tumor cell survival.
Similarly, lipid metabolism is also affected, inducing abnormal
glycerophospholipid- and sphingolipid-related signaling, thereby
leading to tumor cell survival. More recently, it has been reported
that the MAM is a platform for various signaling pathways,
including apoptotic signaling, inflammatory signaling, antiviral
innate immune responses, autophagic signaling, andmetabolism-
related signaling pathways. Interestingly, these signaling pathways
are closely related to both pro- and anti-oncogenic processes.
Although research into the relationship between the MAM and
cancer has only recently begun, it is expected that further charac-
terization of the signaling pathways from the ER, especially from
the MAM, will reveal new insight into novel cancer therapies
(Figure 4).
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